Initial in silico screening identified a compound binding to the XPA-interacting pocket of ERCC1 that enhanced the UV sensitivity of human colon cancer cells by 2-fold, but had a weaker effect on cisplatin sensitivity [24, 25]. The gene discussed is XPA; the disease is colonic neoplasm.